Abstract
Metformin, the only biguanide oral antidiabetic agent available, was first used clinically in the late 1950s. Metformin remains the first-line pharmacologic treatment for type 2 diabetes patients. It can be used as a single agent or in combination therapy with other antidiabetes agents, including insulin. Metformin is absorbed predominately from the small intestine. It is rapidly distributed following absorption and does not bind to plasma proteins. It is excreted unchanged in urine. The elimination half-life of Metformin during multiple dosages in patients with good renal function is approximately 5 hours.
Reference30 articles.
1. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81-98
2. Scheen AJ. Clinical pharmacokinetics of metformin. Clinical pharmacokinetics. 1996;30(5):359-371
3. Flory J, Lipska K. Metformin in 2019. Jama. 2019;321(19):1926-1927
4. Dumitrescu R, Mehedintu C, Briceag I, Purcărea V, Hudita D. Metformin-clinical pharmacology in PCOs. Journal of medicine and life. 2015;8(2):187
5. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: Pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2012;22(11):820
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献